|
DE19531277A1
(de)
*
|
1995-08-25 |
1997-02-27 |
Basf Ag |
Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
|
|
DE19536387A1
(de)
*
|
1995-09-29 |
1997-04-03 |
Basf Ag |
Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
|
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
|
TW568788B
(en)
*
|
1998-10-12 |
2004-01-01 |
Chugai Pharmaceutical Co Ltd |
Polymer combining with phosphoric acid and preparation containing the same
|
|
JP3572213B2
(ja)
*
|
1999-01-18 |
2004-09-29 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロース
|
|
US6733789B1
(en)
|
1999-01-21 |
2004-05-11 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
|
JP2000327701A
(ja)
*
|
1999-05-18 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
低置換度ヒドロキシプロピルセルロース及び固形製剤
|
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
|
DE19934610A1
(de)
*
|
1999-07-23 |
2001-01-25 |
Bayer Ag |
Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
|
|
HUP0202827A2
(en)
|
1999-08-24 |
2002-12-28 |
Siemens Ag |
Suction intake device for an internal combustion machine
|
|
ATE316781T1
(de)
*
|
1999-09-24 |
2006-02-15 |
Janssen Pharmaceutica Nv |
Antivirale feste dispersionen
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
EP1175205B1
(en)
*
|
1999-11-12 |
2006-06-14 |
Abbott Laboratories |
Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
|
|
US20040185099A1
(en)
*
|
2000-01-20 |
2004-09-23 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
US7883721B2
(en)
|
2001-01-30 |
2011-02-08 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
US20050175687A1
(en)
*
|
2001-01-30 |
2005-08-11 |
Mcallister Stephen M. |
Pharmaceutical formulations
|
|
US7842308B2
(en)
|
2001-01-30 |
2010-11-30 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
|
CA2438641A1
(en)
*
|
2001-02-15 |
2002-08-22 |
King Pharmaceuticals, Inc. |
Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
|
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
|
MXPA03011784A
(es)
*
|
2001-06-22 |
2004-04-02 |
Pfizer Prod Inc |
Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
|
|
JP2004534811A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
ポリマーと薬剤の集合体を含む医薬組成物
|
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
|
US20030181524A1
(en)
*
|
2001-10-29 |
2003-09-25 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
|
US20030118652A1
(en)
*
|
2001-11-15 |
2003-06-26 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
|
US20030091633A1
(en)
*
|
2001-11-15 |
2003-05-15 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
|
PL371416A1
(en)
|
2002-02-01 |
2005-06-13 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
KR20040011248A
(ko)
*
|
2002-07-30 |
2004-02-05 |
환인제약 주식회사 |
암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
|
|
PT1530457E
(pt)
|
2002-08-12 |
2009-11-06 |
Bend Res Inc |
Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
|
|
AU2003263162B2
(en)
|
2002-10-24 |
2009-05-07 |
Immupharm A/S |
Pharmaceutical compositions comprising flavonoids and menthol
|
|
JP2006513186A
(ja)
|
2002-12-20 |
2006-04-20 |
ファイザー・プロダクツ・インク |
Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形
|
|
JP2006518380A
(ja)
*
|
2003-01-31 |
2006-08-10 |
スミスクライン・ビーチャム・コーポレイション |
固体分散体組成物
|
|
TW200526274A
(en)
|
2003-07-21 |
2005-08-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
US20080293801A1
(en)
*
|
2003-11-14 |
2008-11-27 |
Pfizer Inc. |
Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
|
|
WO2005056542A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Pfizer Inc. |
Compositions comprising an hiv protease inhibitor
|
|
JP2007520543A
(ja)
|
2004-02-04 |
2007-07-26 |
ファイザー・プロダクツ・インク |
置換キノリン化合物
|
|
TW201240679A
(en)
|
2004-03-12 |
2012-10-16 |
Capsugel Belgium Nv |
Pharmaceutical formulations
|
|
JP4069159B2
(ja)
|
2004-05-25 |
2008-04-02 |
ファイザー・プロダクツ・インク |
テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
EP1804772B1
(en)
*
|
2004-08-12 |
2011-10-05 |
Reckitt Benckiser Healthcare (UK) Limited |
Granules comprising a non-steroidal anti-inflammatory drug and a sugar alcohol made by melt extrusion
|
|
EP1938691A3
(en)
|
2004-12-17 |
2009-07-22 |
Devgen NV |
Nematicidal compositions
|
|
EP1844078B1
(en)
|
2005-02-03 |
2016-09-28 |
Bend Research, Inc |
Pharmaceutical compositions with enhanced performance
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
US20100152299A1
(en)
*
|
2005-05-10 |
2010-06-17 |
Madhav Vasanthavada |
Process for making compositions with poorly compressible therapeutic compounds
|
|
WO2007112286A2
(en)
|
2006-03-24 |
2007-10-04 |
Auxilium Pharmaceuticals, Inc. |
Stabilized compositions containing alkaline labile drugs
|
|
BRPI0709162A2
(pt)
*
|
2006-03-24 |
2011-06-28 |
Auxilum Pharmaceuticals Inc |
processo para a preparação de um laminado extrudado fundido a quente
|
|
US20090258953A1
(en)
*
|
2006-06-07 |
2009-10-15 |
Basf Se |
Use of vinyl acetate-sulfonate copolymers as solubilizers for slightly water-solubable compounds
|
|
US8343547B2
(en)
*
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
PE20090529A1
(es)
*
|
2007-07-06 |
2009-06-04 |
Basf Se |
Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
|
|
BRPI0814294A2
(pt)
*
|
2007-07-19 |
2015-02-03 |
Metabolex Inc |
Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
|
|
EP2219624A2
(en)
|
2007-11-08 |
2010-08-25 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
US20090163561A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
|
WO2009092601A1
(en)
|
2008-01-25 |
2009-07-30 |
Grünenthal GmbH |
Pharmaceutical dosage form
|
|
BRPI0909469A2
(pt)
*
|
2008-03-31 |
2015-12-29 |
Metabolex Inc |
compostos de oximetileno de arila e usos dos mesmos
|
|
CA2723438C
(en)
|
2008-05-09 |
2016-10-11 |
Gruenenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
|
CA2727630A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
AU2009266833B2
(en)
*
|
2008-07-03 |
2013-01-31 |
Novartis Ag |
Melt granulation process
|
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
WO2011009602A1
(en)
|
2009-07-22 |
2011-01-27 |
Grünenthal GmbH |
Hot-melt extruded controlled release dosage form
|
|
PE20120572A1
(es)
|
2009-07-22 |
2012-06-06 |
Gruenenthal Chemie |
Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
|
|
US8410127B2
(en)
*
|
2009-10-01 |
2013-04-02 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
|
BR112012032248A2
(pt)
|
2010-06-23 |
2016-09-13 |
Metabolex Inc |
composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
TWI516286B
(zh)
|
2010-09-02 |
2016-01-11 |
歌林達股份有限公司 |
含陰離子聚合物之抗破碎劑型
|
|
PE20131102A1
(es)
|
2010-09-02 |
2013-10-12 |
Gruenenthal Chemie |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
|
|
JP5903686B2
(ja)
|
2010-12-23 |
2016-04-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
固体分散物を基にした固体徐放製剤
|
|
WO2012110469A1
(en)
|
2011-02-17 |
2012-08-23 |
F. Hoffmann-La Roche Ag |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
|
US9782365B2
(en)
*
|
2011-03-21 |
2017-10-10 |
Sanofi-Aventis Deutschland Gmbh |
Solid ambroxol-containing preparation
|
|
DK2736497T3
(da)
|
2011-07-29 |
2017-11-13 |
Gruenenthal Gmbh |
Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
|
|
LT2736495T
(lt)
|
2011-07-29 |
2017-11-10 |
Grünenthal GmbH |
Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
|
|
CA2864949A1
(en)
|
2012-02-28 |
2013-09-06 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
|
MA37385B1
(fr)
|
2012-04-06 |
2019-09-30 |
Pfizer Inc Etat De Delaware |
Inhibiteurs de diacylglycérol-acyltransférase 2
|
|
RS57913B1
(sr)
|
2012-04-18 |
2019-01-31 |
Gruenenthal Gmbh |
Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
EP2925880B1
(en)
*
|
2012-11-27 |
2020-07-01 |
DSM IP Assets B.V. |
Process for the production of discrete solid extruded particles
|
|
US10154966B2
(en)
|
2013-05-29 |
2018-12-18 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
|
AR096438A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
|
|
IN2014DE01467A
(da)
*
|
2013-06-03 |
2015-07-24 |
Shinetsu Chemical Co |
|
|
MX368846B
(es)
|
2013-07-12 |
2019-10-18 |
Gruenenthal Gmbh |
Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
|
|
KR102388143B1
(ko)
*
|
2013-11-15 |
2022-04-19 |
디에스엠 아이피 어셋츠 비.브이. |
고온-용융 압출에 의한 난용성 화합물의 제형
|
|
EP3073994A1
(en)
|
2013-11-26 |
2016-10-05 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
|
TR201809388T4
(tr)
|
2014-03-17 |
2018-07-23 |
Pfizer |
Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
|
|
JP2017518980A
(ja)
|
2014-05-12 |
2017-07-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
タペンタドールを含む、改変防止即時放出カプセル製剤
|
|
US9872835B2
(en)
|
2014-05-26 |
2018-01-23 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
|
JP2018517676A
(ja)
|
2015-04-24 |
2018-07-05 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時放出および溶媒抽出に対する耐性を有する改変防止製剤
|
|
US10842750B2
(en)
|
2015-09-10 |
2020-11-24 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
KR20180059542A
(ko)
*
|
2015-10-07 |
2018-06-04 |
디에스엠 아이피 어셋츠 비.브이. |
멀티비타민 압출물
|
|
AU2017305392A1
(en)
|
2016-08-03 |
2019-02-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
WO2018115130A1
(en)
|
2016-12-23 |
2018-06-28 |
Hermes Arzneimittel Gmbh |
Oral pharmaceutical composition with improved taste-masking properties
|
|
MX2019010756A
(es)
|
2017-03-10 |
2020-01-20 |
Pfizer |
Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
|
|
SG11202101503RA
(en)
|
2018-08-31 |
2021-03-30 |
Pfizer |
Combinations for treatment of nash/nafld and related diseases
|
|
EP3956031A1
(en)
|
2019-04-19 |
2022-02-23 |
Pfizer Inc. |
Anti-proliferative agents for treating pah
|
|
WO2020234726A1
(en)
|
2019-05-20 |
2020-11-26 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
EP3990452A1
(en)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
|
KR102838870B1
(ko)
|
2020-06-09 |
2025-07-24 |
화이자 인코포레이티드 |
멜라노코르틴 4 수용체 길항제로서의 스피로 화합물 및 그의 용도
|
|
JP7704982B2
(ja)
|
2021-12-01 |
2025-07-08 |
ファイザー・インク |
糖尿病、腎疾患、nashおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての3-フェニル-1-ベンゾチオフェン-2-カルボン酸誘導体
|
|
US20250129048A1
(en)
|
2021-12-06 |
2025-04-24 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
|
EP4598908A1
(en)
|
2022-10-07 |
2025-08-13 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
|
JP2025535295A
(ja)
|
2022-10-18 |
2025-10-24 |
ファイザー・インク |
パタチン様ホスホリパーゼドメイン含有タンパク質3(pnpla3)修飾因子
|
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
|
CN120731201A
(zh)
|
2022-12-16 |
2025-09-30 |
辉瑞公司 |
含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途
|